U.S. Stem Cell Ruling Invites Asian Competition
The ink had barely dried on last week’s U.S. court decision barring the National Institutes of Health from funding embryonic stem cell grants when I received this message from the second annual Stem Cells Asia Regenerative Medicine Congress, which meets in Seoul on October 26 through 28:
Dear Jonathan Moreno,
‘Halt to U.S. Stem Cell Funding May Thwart Search for New Cures’ — Bloomberg News
This is one of the most pertinent reasons why stakeholders of the stem cells arena are now moving to Asia to leverage on Asia’s laissez-faire regulations and capitalize on Asia’s growth potential in stem cell research and application.
And I was in fact quoted in that Bloomberg News story as follows:
“This is a catastrophe. “…It’s now possible that the United States is now taken out of embryonic stem cell research.”
To read the rest of this article, please visit the San Jose Mercury. To read more about how Asia will benefit from the recent injunction on U.S. stem cell research, go here. To read about how the US will fall behind, go here.
Comments on this article